• KU-60019 Workflows for ATM Inhibition Research

  2026-08-26

  Build reproducible glioma experiments around KU-60019, an ATM kinase inhibitor that combines DNA damage response inhibition with radiosensitization and migration assays. A metabolism-aware workflow also tests whether ATM suppression shifts nutrient scavenging toward macropinocytosis, creating a practical bridge between radiation biology and tumor-cell adaptation.

• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-08-26

  A 2025 study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase reshapes circulating 14,15-EET and 14,15-DHET, inflammatory signaling, and Nrf2-dependent osteoclastogenesis. By combining patient samples, an ovariectomy-induced mouse model, liver-specific perturbation, osteoclast cultures, metabolite analysis, and transcriptomics, the work provides a mechanistic framework for studying redox imbalance in osteoporosis.

• Vitamin D/VDR Signaling in Endometrial Decidualization

  2026-08-25

  Guo and colleagues show that vitamin D promotes human endometrial stromal cell decidualization through VDR-dependent regulation of aromatase and estrogen signaling. The study combines loss- and gain-of-function experiments with ChIP-qPCR, providing a mechanistic framework for evaluating 1,25-dihydroxy vitamin D3 in endometrial receptivity research.

• Anti-ROR1 Antibody: Assay Logic for Zilovertamab

  2026-08-25

  Anti-ROR1 Antibody (Zilovertamab) can do more than confirm ROR1 binding: it can anchor a decision-based assay strategy for target engagement, pathway modulation, and translational interpretation. This article connects ROR1 assay design with mechanistic lessons from DON-induced liver injury without implying untested cross-disease efficacy.

• Saracatinib (AZD0530): From Src Biology to Translation

  2026-08-24

  Saracatinib (AZD0530) offers translational researchers a mechanistically focused way to interrogate Src family kinase and Abl signaling across cancer models. This article connects its effects on proliferation, migration, adhesion, and tumor growth with emerging evidence that SFK-dependent synaptic signaling can also shape ketamine responsiveness—while clearly separating established findings from cross-domain hypotheses.

• WZ4003 Lowers Tau pSer356 in Brain Models

  2026-08-24

  Taylor et al. linked tau phosphorylation at Ser356 to Alzheimer’s disease pathology and showed that the NUAK1/2 inhibitor WZ4003 lowers this modification in live human brain slice cultures. The study also reveals important model-dependent effects in mouse organotypic slices, providing a framework for interpreting NUAK inhibition in translational neurodegeneration research.

• JXY, TLR4, and M1 Macrophages in Colitis-Associated CRC

  2026-08-23

  Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-associated state through TLR4-linked signaling. The study combines an orthotopic cancer model with macrophage assays and pharmacological pathway interrogation, providing a useful framework for connecting tumor progression with immune-microenvironment remodeling.

• Thymoquinone Workflows for Cardiotoxicity Research

  2026-08-22

  Build reproducible doxorubicin cardiotoxicity assays around Thymoquinone, from solvent handling through ferroptosis, oxidative-stress, and cardiac-function readouts. The workflow separates study-matched mouse dosing from practical cell-culture optimization while highlighting controls that distinguish antioxidant protection from nonspecific cytotoxicity.

• IGFBP2–THBS1 Mechanism in GH-Treated ISS

  2026-08-22

  This study identifies an IGFBP2–THBS1 regulatory axis that links growth hormone treatment to IGF-1 signaling, chondrocyte proliferation, and hypertrophic differentiation in idiopathic short stature. Its combination of patient plasma data, bioinformatic interaction prediction, and gain- and loss-of-function experiments provides a mechanistic framework for studying variable responses to GH therapy.

• β-Elemene: From Adipogenesis to Assay Insight

  2026-08-21

  β-Elemene is more than an adipogenesis inhibitor: it is a context-dependent tool for separating phenotype, metabolism, and pathway response. This article interprets recent 3T3-L1 evidence and translates it into reproducible assay and cross-domain research decisions.

• Everolimus (RAD001): Readouts That Matter

  2026-08-20

  Everolimus (RAD001) is an orally bioavailable mTOR inhibitor whose pathway activity should be separated from cytostasis and cell death. This assay-centered guide shows how to design more informative cancer experiments by integrating mechanistic, proliferation, and apoptosis readouts.

• IRG1-Itaconate Control of TBK1 and Type I IFN

  2026-08-20

  A 2025 Cell Reports study identifies the IRG1–itaconic acid axis as a metabolic feedback mechanism that restrains excessive TBK1-driven type I interferon production. The work connects itaconic acid–dependent alkylation of TBK1 at Cys605 with impaired dimerization and introduces ITA-5 and ITA-9 as candidate inhibitors for IFN-I-mediated hyperinflammation.

• Rapamycin (Sirolimus) for mTOR Assays

  2026-08-19

  Rapamycin (Sirolimus) provides a precise chemical perturbation strategy for mTOR-driven studies spanning cancer, autophagy, immunology, and mitochondrial disease models. This practical guide connects dose–time design with EBV-associated gastric cancer biology, pathway validation, and troubleshooting for reproducible cell assays.

• PP 2 (AG 1879): From Src Biology to Translation

  2026-08-19

  PP 2 (AG 1879) is more than a Src-family kinase reagent: it is a context-dependent probe for separating target engagement from pathway causality. This article connects its cancer and immune applications with vascular evidence showing that Src inhibition can reduce contraction without mediating NADPH oxidase-derived ROS effects, providing a practical framework for translational study design.

• TPPU: Soluble Epoxide Hydrolase Inhibitor Workflows

  2026-08-18

  TPPU is a nanomolar soluble epoxide hydrolase inhibitor for connecting fatty acid epoxide signaling with inflammatory pain, osteoclastogenesis, and Nrf2 biology. This workflow-focused guide shows how to formulate it, confirm EET/DHET target engagement, and troubleshoot cell, lipidomics, and cross-species experiments.

8317 records 1/555 page Next 12345 下5页 Last page